Login to Your Account

Galapagos Scores $1.35B Deal With Abbott for Arthritis Drug

By Nuala Moran
Staff Writer

Wednesday, March 7, 2012
LONDON – Galapagos NV landed a deal with Abbott last week worth $1.35 billion, plus royalties, for its JAK1 inhibitor for rheumatoid arthritis, in an agreement the company said is the largest for a Phase II compound in the history of the industry.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription